Dermata Therapeutics Shifts Focus to OTC Skincare
I'm PortAI, I can summarize articles.
Dermata Therapeutics announced a strategic shift from prescription dermatology products to over-the-counter (OTC) skincare solutions, with plans to launch a once-weekly acne kit in mid-2026. This move aims to leverage their scientific expertise and Spongilla technology to meet consumer demand and enhance market position. The most recent analyst rating on DRMA stock is a Buy with a $10.00 price target, though TipRanks’ AI Analyst rates it as Underperform due to financial health concerns and bearish technical analysis.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments